Poolbeg Pharma PLC
POLB.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.00 | -0.00 | 0.00 |
| FCF Yield | -13.47% | -8,931.38% | -16,413.22% | -4,688.42% |
| EV / EBITDA | -4.60 | 2.60 | 3.26 | 9.02 |
| Quality | ||||
| ROIC | -73.22% | -30.45% | -26.69% | -10.53% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.78 | 0.98 | 0.91 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -18.72% | 18.99% | -122.95% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 1.30 | 2.61 | 3.26 | 9.04 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -27.03 | 0.00 |
| Cash Conversion Cycle | -528.29 | -1,109.04 | -4,126.77 | -1,601.94 |